Small Cell Lung Cancer News and Research

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

New biomarkers can predict patients' response to certain drugs

19. November 2009 04:02

Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects. [More]

50ccea28-a9bb-4b4c-9116-c045d0269177|0|.0

Posted in: Medical Science News | Medical Condition News

Tags: Biomarker, Breast Cancer, Cancer, Cell, Cell Proliferation, Cervical Cancer, Colon Cancer, Head and Neck Cancer, Lung Cancer, Melanoma, Non-Small Cell Lung Cancer, Oncogene, Ovarian Cancer, Radiotherapy, Renal Cell Carcinoma, Small Cell Lung Cancer, Sorafenib, Tamoxifen, VEGF

Opiate-based painkillers can increase tumor-cell proliferation, says new study

19. November 2009 01:37

Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells. [More]

93413953-874e-4748-8590-f191a2cb10c2|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Anesthesiology, Angiogenesis, Brain, Cancer, Cell, Cell Proliferation, Constipation, Life Expectancy, Lung Cancer, Metastasis, Morphine, Non-Small Cell Lung Cancer, Prostate Cancer, Small Cell Lung Cancer

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

19. November 2009 00:22

Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors. [More]

9f19f465-9b09-4558-8717-5dc5f9c0f5b8|0|.0

Posted in: Drug Trial News | Pharmaceutical News

Tags: Anorexia, Biopsy, Biotechnology, Cancer, Cell, Cell Proliferation, Chemotherapy, Colorectal Cancer, Diarrhea, Erlotinib, Head and Neck Cancer, Hepatocellular Carcinoma, Lung Cancer, Nausea, Non-Small Cell Lung Cancer, Pfizer, Radiotherapy, Small Cell Lung Cancer, Squamous Cell Carcinoma, Vomiting

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

18. November 2009 08:40

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models. [More]

7105e9d6-13ab-4fd4-afa9-3e55eccba03a|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Acute Lymphoblastic Leukemia, Apoptosis, Breast Cancer, Cancer, Cell, Chronic Myeloid Leukemia, Colon Cancer, Erlotinib, Gleevec, Hospital, Leukemia, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma, Myeloid Leukemia, Non-Small Cell Lung Cancer, Oncology, Paclitaxel, Pancreatic Cancer, Prostate Cancer, Small Cell Lung Cancer, Sunitinib, Tarceva, Xenograft

Study to test anti-tumor effects of AEOL 10150 initiated

18. November 2009 03:04

Aeolus Pharmaceuticals, Inc. announced today the initiation of a study to test the anti-tumor effects of AEOL 10150 when combined with radiation and chemotherapy in nude mice bearing human non-small cell lung cancer (NSCLC) xenografts. [More]

9cc6e5d3-b581-4e45-8159-6d64d2a5c2da|0|.0

Posted in: Medical Science News | Medical Condition News | Pharmaceutical News

Tags: Angiogenesis, Anti-Inflammatory, Antioxidant, Cancer, Cell, Chemotherapy, Epilepsy, Fibrosis, Hypoxia, Lung Cancer, Macrophage, Manganese, Non-Small Cell Lung Cancer, Oxidative Stress, Paclitaxel, Radiation Exposure, Radiation Therapy, Radiotherapy, Small Cell Lung Cancer, Stress, Toxicology, VEGF, Weight Loss

Erbitux recognized as one of the major clinical cancer advances of 2009

16. November 2009 09:21

The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with 1st-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). [More]

f2838858-9c45-4eb8-a649-a6b5654e9bab|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Acne, Antibody, Cancer, Cell, Cetuximab, Chemotherapy, Colorectal Cancer, Endocrinology, Fertility, Glioblastoma, Head and Neck Cancer, Hypersensitivity, Infertility, Irinotecan, Liposome, Lung Cancer, Metformin, Monoclonal Antibody, Multiple Sclerosis, Non-Small Cell Lung Cancer, Oncology, Oxaliplatin, Radiotherapy, Small Cell Lung Cancer, Smoking, Squamous Cell Carcinoma, Vaccine

Bend Memorial Clinic set to begin Phase III lung cancer trial

11. November 2009 23:12

The Bend Memorial Clinic is recruiting patients for a Phase III lung cancer trial aimed at preventing the disease’s recurrence in previously treated patients. Specifically, the trial is evaluating the potential of an immunotherapy called Antigen-Specific Cancer Immunotherapeutic (ASCI) for the treatment of Non-Small Cell Lung Cancer (NSCLC). [More]

ee9a281b-f910-4310-a0bb-e6b6af10a444|0|.0

Posted in: Medical Science News | Medical Condition News

Tags: Biomarker, Cancer, Cell, Chemotherapy, Immunotherapy, Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer

Poniard Pharmaceuticals to present picoplatin Phase 2 trial data at the AACR-NCI -EORTC conference

11. November 2009 01:56

Poniard Pharmaceuticals, Inc. today announced that the Company will present updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC) and final results from its Phase 1 cardiac safety trial. [More]

db858b2b-9147-4c24-ba80-0544b269401e|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Cancer, Cell, Chemotherapy, Colorectal Cancer, Fluorouracil, Lung Cancer, Neuropathy, Oncology, Prostate Cancer, Small Cell Lung Cancer

Potential new drug for lung cancer eliminates tumors in mice

11. November 2009 00:24

A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer. [More]

2a9c5c1b-a300-4337-9787-61d952dfe335|0|.0

Posted in: Medical Science News | Medical Condition News

Tags: Apoptosis, Cancer, Cell, Cell Proliferation, Chemotherapy, Cisplatin, DNA, Growth Hormone, Lung Cancer, Oncology, Radiotherapy, Small Cell Lung Cancer

PET scanning emerges as an important tool in the evaluation of lung cancer

7. November 2009 01:28

A rapid decline in metabolic activity on a PET scan after radiation therapy for non-small cell lung cancer is correlated with good local tumor control, according to a study presented by researchers at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting. [More]

9874928e-3923-4ff8-b7e9-188c8728a3d4|0|.0

Posted in: Device / Technology News | Medical Condition News

Tags: Cancer, Cell, Hospital, Lung Cancer, Non-Small Cell Lung Cancer, Oncology, Radiation Therapy, Small Cell Lung Cancer

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

5. November 2009 23:20

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the third quarter ending September 30, 2009. [More]

e2e66afc-1a09-40ac-b5e8-cf8599dc974d|0|.0

Posted in: Business / Finance

Tags: Abraxane, Anthracycline, Biotechnology, Breast Cancer, Cancer, Cell, Chemotherapy, Investment, Lung Cancer, Melanoma, Nanoparticle, Non-Small Cell Lung Cancer, Oncology, Paclitaxel, Pancreatic Cancer, Small Cell Lung Cancer

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

5. November 2009 07:59

ArQule, Inc. today reported its results of operations for the fiscal quarter and nine months ended September 30, 2009. [More]

09ef16a1-b516-4e5f-bf29-b4007205e95b|0|.0

Posted in: Business / Finance

Tags: Adenosine, Biotechnology, Cancer, Cell, DNA, Erlotinib, Fibroblast, Gemcitabine, Hepatocellular Carcinoma, Kinase Inhibitor, Lung Cancer, Non-Small Cell Lung Cancer, Oncology, Pancreatic Cancer, Small Cell Lung Cancer, Soft Tissue Sarcoma, Sorafenib

Idera Pharmaceuticals announces financial results for the third quarter of 2009

5. November 2009 07:54

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. [More]

8ff77ca2-571a-46e3-884c-ad4815778782|0|.0

Posted in: Business / Finance

Tags: Allergy, Antisense, Arthritis, Asthma, Avastin, Bevacizumab, Bone, Cancer, Cell, Collagen, Colorectal Cancer, Cytokines, Diarrhea, DNA, Erlotinib, Etanercept, Gene Expression, Headache, Hepatitis C, Kidney Cancer, Lung Cancer, Nausea, Non-Small Cell Lung Cancer, Oligonucleotides, Oncology, Pathology, Pfizer, Potassium, Renal Cell Carcinoma, Respiratory Disease, Rheumatology, Ribavirin, Small Cell Lung Cancer, Tarceva, Vaccine, Virus

Cell Therapeutics reports financial results for the third quarter and nine months ended September 30, 2009

5. November 2009 02:57

Cell Therapeutics, Inc. today reported recent achievements and financial results for the third quarter and nine months ended September 30, 2009, which included a 45% decrease in the net loss attributable to common shareholders for the nine month period in 2009 compared to the same period in 2008. [More]

a9ff6416-bf6f-4525-aaf3-8c5acc09ae6d|0|.0

Posted in: Business / Finance

Tags: Biotechnology, Cancer, Cell, Hodgkin's Lymphoma, Investment, Lung Cancer, Lymphoma, New Drug Application, Non-Hodgkin's Lymphoma, Non-Small Cell Lung Cancer, Oncology, Ovarian Cancer, Small Cell Lung Cancer

FDA approves SPA Protocol Amendment for Lucanix Phase III clinical trial

4. November 2009 05:46

NovaRx Corporation announced today that the Company has successfully negotiated and received FDA approval for a Special Protocol Assessment (SPA) Protocol Amendment to the pivotal Lucanix® Phase III clinical trial in patients with Non-Small Cell Lung Cancer (NSCLC). [More]

7a86e368-11fa-4c0a-ab61-b39e6bc759d5|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Brain, Brain Cancer, Cancer, Cell, Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Vaccine

<< Previous posts

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

Free!

Recent Comments

Twitter

Information

Small Cell Lung Cancer News and Research

New biomarkers can predict patients' response to certain drugs

Opiate-based painkillers can increase tumor-cell proliferation, says new study

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Study to test anti-tumor effects of AEOL 10150 initiated

Erbitux recognized as one of the major clinical cancer advances of 2009

Bend Memorial Clinic set to begin Phase III lung cancer trial

Poniard Pharmaceuticals to present picoplatin Phase 2 trial data at the AACR-NCI -EORTC conference

Potential new drug for lung cancer eliminates tumors in mice

PET scanning emerges as an important tool in the evaluation of lung cancer

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Cell Therapeutics reports financial results for the third quarter and nine months ended September 30, 2009

FDA approves SPA Protocol Amendment for Lucanix Phase III clinical trial

Recent Articles

Free!

Recent Comments

Twitter

Information

Small Cell Lung Cancer News and Research

Medical News Cloud

Recent Articles